| REVIEW ARTICLE |
|
| Year : 2021 | Volume
: 35
| Issue : 1 | Page : 3-7 |
|
|
Severe asthma with fungal sensitization
Rajendra Prasad1, Syed Ahmed Hussain Kazmi1, Rishabh Kacker1, Nikhil Gupta2
1 Department of Pulmonary Medicine, Era's Lucknow Medical College and Hospital, Lucknow, Uttar Pradesh, India
2 Department of General Medicine, Dr.Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Correspondence Address:
Dr. Rajendra Prasad
A-28, Sector J, Aliganj, Lucknow - 226 024, Uttar Pradesh
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijaai.ijaai_64_20
|
|
|
Bronchial asthma is an inflammatory disease of the airways, which may be worsened due to many extrinsic factors. The most common trigger is the continuous exposure to allergens, of which fungal agents are important factors. A new phenotype of asthma called severe asthma with fungal sensitization (SAFS) has been described. It is diagnosed by the presence of severe asthma, fungal sensitization, and absence of allergic bronchopulmonary aspergillosis. SAFS is more of a diagnosis of exclusion. Treatment of SAFS initially should be similar to that of severe asthma including humanized anti-IgE monoclonal antibody and other biologics. These patients usually do not have their symptoms relieved with conventional treatment of severe asthma, i.e. high-dose inhaled corticosteroids and long-acting bronchodilators. Prolonged use of oral corticosteroids and pulse high-dose intravenous corticosteroid is effective. There are some evidence implicating the role of antifungal agents including itraconazole, but its use as a specific therapy requires further studies.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
